VANCOUVER, BC, March 20,
2024 /PRNewswire/ - Numinus Wellness Inc.
("Numinus" or the "Company") (TSX: NUMI) (OTCQX:
NUMIF), a mental health care company advancing traditional and
innovative behavioral health treatments with a focus on safe,
evidence-based psychedelic-assisted therapies, announces that it
has submitted a Clinical Trial Application to Health Canada to
examine the feasibility of a group model in MDMA-assisted
psychotherapy enrolling trainee practitioners as participants.
If approved, the trial would allow Numinus to study
MDMA-assisted psychotherapy with groups and better understand the
optimum number of therapists required to deliver the programs
safely. It may also provide eligible trainees with the opportunity
to build core competencies and legally experience MDMA.
"As research into MDMA's efficacy in addressing serious mental
conditions is increasing, it is particularly important that
practitioners advance their knowledge of optimum delivery in a
clinical setting," said Payton
Nyquvest, Numinus Founder and CEO. "Our goal in designing
this study is to explore the feasibility of a group model and take
steps to help establish best practices in group-based therapy for
MDMA and contribute to the body of evidence of its safety."
"Considering the large potential patient population that could
be seeking care should MDMA-assisted therapy receive approval, it
will be essential for clinics and practitioners to gain the
knowledge and experience to deliver this groundbreaking treatment
for PTSD," added Rick Doblin,
PhD., an unpaid volunteer Numinus Strategic Advisor. "This study
has the potential to significantly enhance patient outcomes by
providing a means for practitioners to gain valuable insights."
The clinical trial is formally titled "Phase 1 Exploration of
Feasibility and Optimal Therapist Numbers in Group Model
MDM-Assisted Psychotherapy: A Study on Safety, Delivery, and
Practitioner Training." If approved, it will be the first of its
kind. Details on participating in the clinical trial will be posted
on the Numinus website at
https://numinus.com/en-ca/clinical-trials/.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be
well through the development and delivery of innovative mental
health care and access to safe, evidence-based psychedelic-assisted
therapies. The Numinus model – including psychedelic research,
clinic care and practitioner training – is at the forefront of a
transformation aimed at healing rather than managing symptoms for
depression, anxiety, trauma, pain and substance use. At Numinus, we
are leading the integration of psychedelic-assisted therapies into
mainstream clinical practice and building the foundation for a
healthier society.
Learn more at www.numinus.com and follow us
on LinkedIn, Facebook, Twitter,
and Instagram.
Forward-looking
statements
Statements and other information contained in this press
release about anticipated future events constitute forward-looking
statements. Forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate",
"believe", "plan", "estimate", "expect" and "intend" and statements
that an event "may", "will", "should", "could" or "might" occur or
other similar expressions. Forward-looking statements are subject
to risks and uncertainties and other factors that could cause
actual results to differ materially from those contained in the
forward-looking statements, including approval of MDMA-assisted
therapy for any indication or at all; restrictions that may be
placed on the use of MDMA by regulatory authorities; safety and
efficacy of MDMA-assisted therapy; acceptance, uptake and
commercialization of MDMA-assisted therapy; approval of the
clinical trial by Health Canada or the FDA, as applicable;
availability of suitable subjects for the trial; the effect, if
any, of having obtained certification on any particular trainee or
such trainee's business or profile; and other risks that are set
forth in our annual information form dated November 29, 2023 and available on SEDAR at
www.sedarplus.ca. Forward-looking statements are based on
estimates and opinions of management at the date the statements are
made. Numinus does not undertake any obligation to update
forward-looking statements even if circumstances or management's
estimates or opinions should change except as required by
applicable laws. Investors should not place undue reliance on
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/numinus-wellness-submits-clinical-trial-application-302093956.html
SOURCE Numinus Wellness Inc.